Insider Transactions in Q4 2020 at Dexcom Inc (DXCM)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Bona fide gift
|
Direct |
950
-2.84%
|
-
|
|
Dec 28
2020
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.55%
|
$177,500
$355.39 P/Share
|
|
Dec 23
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-1.49%
|
$399,600
$360.59 P/Share
|
|
Dec 23
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.26%
|
$389,519
$361.24 P/Share
|
|
Dec 16
2020
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
1,250
-3.08%
|
$442,500
$354.34 P/Share
|
|
Dec 15
2020
|
Bridgette P Heller Director |
SELL
Open market or private sale
|
Direct |
375
-9.81%
|
$133,500
$356.65 P/Share
|
|
Dec 01
2020
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,154
-23.92%
|
$2,000,050
$325.0 P/Share
|
|
Dec 01
2020
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
13,233
-2.14%
|
$4,261,026
$322.2 P/Share
|
|
Nov 24
2020
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-5.04%
|
$192,000
$320.37 P/Share
|
|
Nov 23
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-9.1%
|
$352,980
$318.99 P/Share
|
|
Nov 23
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-1.74%
|
$343,122
$318.99 P/Share
|
|
Nov 19
2020
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
8,207
+50.0%
|
-
|
|
Nov 16
2020
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
1,000
-1.44%
|
$339,000
$339.94 P/Share
|
|
Nov 10
2020
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
632
-5.04%
|
$212,352
$336.22 P/Share
|
|
Nov 08
2020
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,707
+50.0%
|
-
|
|
Oct 29
2020
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
13,830
-0.72%
|
$4,743,690
$343.75 P/Share
|
|
Oct 23
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-1.08%
|
$447,330
$403.7 P/Share
|
|
Oct 23
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.25%
|
$434,837
$403.66 P/Share
|
|
Oct 15
2020
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
1,000
-1.35%
|
$395,000
$395.73 P/Share
|
|
Oct 14
2020
|
Richard Doubleday EVP Chief Commercial Officer |
BUY
Other acquisition or disposition
|
Indirect |
13,313
+50.0%
|
-
|
|
Oct 14
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
13,313
-28.44%
|
-
|
|
Oct 11
2020
|
Kyle Malady Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,272
+50.0%
|
-
|
|
Oct 01
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
200
-0.32%
|
$84,000
$420.0 P/Share
|